Nintedanib Eugia (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR 1‑3, FGFR 1‑3 and PDGFR‑α/β—preventing their activation by natural ligands. This inhibition reduces endothelial cell proliferation, fibroblast activation and new blood‑vessel formation, which in turn limits fibrotic remodeling in the lungs and hampers the vascular supply that many tumors require for growth.

The dose of Nintedanib Eugia is individualized by the prescribing physician based on the specific indication, patient weight, renal and hepatic function, and any concomitant medications. The prescriber determines the appropriate strength, frequency and duration of therapy, and patients should follow the written prescription and any monitoring plan provided by their healthcare professional.

The safety of Nintedanib in pregnancy and lactation has not been established. Animal studies have shown potential risks, and the drug is classified as contraindicated for use in pregnant or nursing women unless the potential benefit justifies the risk. Women of childbearing potential should use effective contraception during treatment and discuss any concerns with their physician.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming eligibility, then replies with pricing, availability, shipping details (including any required temperature control) and the necessary import documentation.

Compared with pirfenidone, another approved antifibrotic for IPF, Nintedanib targets a broader range of tyrosine‑kinase receptors, offering a different mechanism that may be advantageous in patients with overlapping vascular or oncologic conditions. Clinical trials have shown comparable efficacy in slowing lung‑function decline, while the safety profile differs, with Nintedanib more frequently causing gastrointestinal effects and pirfenidone associated with photosensitivity.

Nintedanib Eugia should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store it in bathrooms or near heat sources. If the packaging is damaged, contact the supplier for replacement to ensure product integrity.

Nintedanib Eugia is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets (or capsules, depending on the marketed form) are swallowed whole with a full glass of water and should not be crushed, chewed, or split unless specifically instructed by a healthcare professional. Patients should follow the dosing schedule prescribed by their clinician and attend regular follow‑up visits for monitoring.

The most serious adverse events reported with Nintedanib include hepatotoxicity, which may present as elevated liver enzymes or, rarely, severe liver injury; bleeding complications, especially in patients receiving anticoagulants or antiplatelet drugs; and cardiovascular events such as arterial thromboembolism or myocardial infarction. Prompt reporting of symptoms like jaundice, unusual bruising, chest pain or shortness of breath to a healthcare provider is essential.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any of its excipients. It should also be avoided in individuals with severe hepatic impairment, active bleeding disorders, or uncontrolled hypertension. Patients currently on strong CYP3A4 inhibitors or those with a history of serious cardiovascular events should discuss alternative therapies with their physician before initiating treatment.